Refsum's Disease—Use of the Intestinal Lipase Inhibitor, Orlistat, as a Novel Therapeutic Approach to a Complex Disorder

<table>Shortening of AF’s fourth toe, characteristic of Refsum’s Disease.</table>

Journal of Obesity

Figure 2: Refsum's Disease—Use of the Intestinal Lipase Inhibitor, Orlistat, as a Novel Therapeutic Approach to a Complex Disorder 